2Bick RL. Cancer-associated thrombosis[J]. N Eng J Med, 2003, 349(2): 109-111.
3Letai A, Kuter DJ. Cancer, coagulation, and anticoagulation[J]. Oncologist, 1999, 4(6): 443--449.
4Pruemer J. Prevalence, causes, and impact of cancer-associated thrombosis[]]. AmJ Health Syst Pharm, 2005, 62(22 Suppl 5): s4--s6.
5Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: risk analysis using Medicare claims data[J]. Medicine, 1999, 78(5): 285-291.
6Burris HA. Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care[J]? Semin Oncol, 2006, 33(2 Suppl 4):S3-S16; quiz S41-S42.
7BaronJA, Gridley G, Weiderpass E, et al. Venous thromboembolism and cancer[J]. Lancet, 1998, 351(9109): 1077-1080.
8Sorensen HT, Mellemkjaer L, Steffensen FH, et al.. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism[J]. N EnglJ Med, 1998, 338 (17): 1169-1173.
9GomuzJ, Pearson SD, Greager MA, et al. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis[J]. Ann Intern Med, 1996, 125 (10): 785-793.
10Murchison JT, Wyfie L, Stockton DL. Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study[]]. BrJ Cancer, 2004, 91(1): 92-95.
